Mathew Holderfield
Revolution Medicines, Redwood City, USA
Matt has over 15 years of drug discovery and development experience across large pharma, government, and biotech, having worked previously for Novartis, UCSF Helen Diller Family Comprehensive Cancer Center, and Frederick National Laboratories for Cancer Research, where he has maintained a consistent focus on developing strategies to treat RAS and MAPK pathway addicted cancers. Early in his career, Matt helped to elucidate the mechanism of action for RAF kinase inhibitors and mechanisms of BRAF oncogene activation. Now at Revolution Medicines, Matt is directing the cancer cell and systems biology groups where he supports several RAS targeted inhibitor programs that are in preclinical and clinical stage development.
Matt has over 15 years of drug discovery and development experience across large pharma, government, and biotech, having worked previously for Novartis, UCSF Helen Diller Family Comprehensive Cancer Center, and Frederick National Laboratories for Cancer Research, where he has maintained a consistent focus on developing strategies to treat RAS and MAPK pathway addicted cancers. Early in his career, Matt helped to elucidate the mechanism of action for RAF kinase inhibitors and mechanisms of BRAF oncogene activation. Now at Revolution Medicines, Matt is directing the cancer cell and systems biology groups where he supports several RAS targeted inhibitor programs that are in preclinical and clinical stage development.
